In This Section

Recent Press Releases

December 16, 2016

Vancouver, BC, December 16, 2016 - Novelion Therapeutics (NASDAQ: NVLN) (TSX: NVLN), today announced that subsidiary Aegerion Pharmaceuticals completed the first commercial shipment of JUXTAPID® (lomitapide) to a patient in Japan. In September 2016, JUXTAPID was approved by Japan’s Ministry of Health, Labor & Welfare (MHLW) for patients with homozygous familial hypercholesterolemia (HoFH).

December 5, 2016

Transaction provides new royalty and potential milestone revenues, opportunity to reduce cost structure, and continuity of patient access to lomitapide